Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Prostate cancer: Bone density testing--essential or extraneous?

Yu EY.

Nat Rev Urol. 2013 Jan;10(1):11-2. doi: 10.1038/nrurol.2012.240. Review. No abstract available.

PMID:
23229500
2.

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.

Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.

Can J Urol. 2007 Jun;14(3):3551-9.

PMID:
17594745
3.

The impact of osteoporosis in men treated for prostate cancer.

Oefelein MG, Resnick MI.

Urol Clin North Am. 2004 May;31(2):313-9. Review.

PMID:
15123410
4.

Prostate cancer, osteoporosis and fracture risk.

Allain TJ.

Gerontology. 2006;52(2):107-10. Review.

PMID:
16508318
5.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Review. German.

PMID:
22875632
6.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
7.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105.

PMID:
21807761
8.

[Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].

Izumi K, Mizokami A, Namiki M.

Clin Calcium. 2010 Feb;20(2):175-81. doi: CliCa1002175181. Review. Japanese.

PMID:
20118508
9.

Prostate cancer treated with androgen deprivation therapy has consequences for bone.

Adler RA.

Endocrine. 2014 Apr;45(3):339-40. doi: 10.1007/s12020-013-0113-x. No abstract available.

PMID:
24366636
10.

Cancer treatment-induced bone loss in breast and prostate cancer.

Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI.

J Clin Oncol. 2008 Nov 20;26(33):5465-76. doi: 10.1200/JCO.2008.18.4184. Review.

PMID:
18955443
11.

Risk of fracture after androgen deprivation for prostate cancer.

Walsh PC.

J Urol. 2005 Sep;174(3):929-30. No abstract available.

PMID:
16093991
12.

More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.

Barrass BJ, Thurairaja R, Persad RA.

BJU Int. 2004 Jun;93(9):1175-6. No abstract available.

13.

Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.

Bruder JM.

Curr Urol Rep. 2005 May;6(3):157-8. Review. No abstract available.

PMID:
15869718
14.

[Prevention of bone loss in a patient receiving androgen deprivation therapy].

Rolfes N, Lümmen G.

Urologe A. 2011 Nov;50(11):1383-6. doi: 10.1007/s00120-011-2655-y. Review. German.

PMID:
21800195
15.

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Ross RW, Small EJ.

J Urol. 2002 May;167(5):1952-6. Review.

PMID:
11956415
16.

Bisphosphonates in prostate cancer: where are we and where should we go?

Saad F.

J Natl Cancer Inst. 2003 Sep 3;95(17):1262-3. No abstract available.

17.

Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.

Cai T, Bartoletti R.

J Clin Oncol. 2007 Aug 1;25(22):3385; author reply 3385-6. No abstract available.

PMID:
17664492
18.

Fracture risk in Danish men with prostate cancer: a nationwide register study.

Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K.

BJU Int. 2007 Oct;100(4):749-54.

19.

Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.

Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.

Cancer. 2004 Aug 1;101(3):541-9. Erratum in: Cancer. 2004 Nov 15;101(10):2370.

20.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

Items per page

Supplemental Content

Support Center